Results 31 to 40 of about 7,007,196 (291)
PLoS ONE, 2020 ObjectiveThe objective of this study was to evaluate the relationship between concurrent physician-based mental health services, all-cause mortality, and acute health service use for individuals enrolled in Opioid Agonist Treatment in Ontario, Canada ...
Kristen A Morin +6 more
doaj +1 more source
Frontiers in Psychiatry, 2022 The increasing prevalence of illicit stimulant use among those in opioid treatment programs poses a significant risk to public health, stimulant users have the lowest rate of retention and poorest outcomes among those in addiction treatment, and current ...
Christopher S. Stauffer +8 more
doaj +1 more source
BUPRENORPHINE IN OPIOID ADDICTION TEREATMENT: STUDIES WITH METHADONE COMPARISON
Psychiatry and Clinical Psychopharmacology, 2021 Methadone maintenance treatment is the most widely used pharmacological treatment approach for opioid addiction in many countries. In spite of many benefits that was gained after the usage of full agonist methadone, especially high numbers of patients ...
E.Cüneyt Evren +3 more
doaj
BMC Psychiatry, 2022 Background The last decade has shown a remarkable increase in the rates of illicit opioid use in Canada and internationally, which is associated with large increases in opioid related morbidity and mortality.
Joseph Sadek, Joseph Saunders
doaj +1 more source
Suboxone: History, controversy, and open questions
Frontiers in Psychiatry, 2022 There are more than 200 opioid overdose deaths each day in the US. In combating this epidemic we look to available treatment tools. Here, we find only three medications approved by the Food and Drug Administration (FDA) for the treatment of opioid use ...
Andy Sivils +3 more
doaj +1 more source
Angewandte Chemie, EarlyView.Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma +5 more
wiley +2 more sources
Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon
Harm Reduction Journal, 2017 Background Opioid agonist therapy has been widely used to reduce harms among individuals with opioid use disorder but its effectiveness has not been evaluated in the Middle East North African (MENA) region.
Ali Ghaddar, Zeinab Abbas, Ramzi Haddad
doaj +1 more source
Changes and trends in medication-assisted treatment in Israel
Israel Journal of Health Policy Research, 2023 Background As opioid prescription in Israel is increasing, there is a growing need for monitoring opioid use disorder and providing opioid agonist therapy.
Adi Marom, Iris Levy, Paola Rosca
doaj +1 more source
, 2022 Although opioid agonist treatment (OAT) substantially reduces morbidity and mortality in individuals with opioid dependence, mortality is still higher than in the general population.
Bech, Anne Berit
core +1 more source
Patient Preference and Adherence, 2022 Sophia Dobischok,1 Rebecca K Metcalfe,1 Elizabeth Angela Matzinger,1 Kurt Lock,1,2 Scott Harrison,3 Scott MacDonald,3 Sherif Amara,4 Martin T Schechter,1,5 Nick Bansback,1,5 Eugenia Oviedo-Joekes1,5 1Centre for Health Evaluation & Outcome Sciences ...
Dobischok S +9 more
doaj